Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma’s Pipeline Getting Fuller; Parexel Finds 8.2% Jump In Trial Starts

Executive Summary

While pharmaceutical companies have been bemoaning the dearth of new drugs coming on the market, things may be looking up

You may also be interested in...



India And China Not Yet Major Sites For FDA-Regulated Trials, Parexel Finds

While India now ranks among the top 10 countries conducting FDA-regulated clinical trials, it has yet to see a major influx of trial work

Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D

Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization

Pharma Maintains Steady Pace Of IND Submissions in 2005, Parexel Says

Oncologics led the pharmaceutical industry's investigational new drug application submissions over other drug classes in fiscal year 2005, according to an analysis by Parexel

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel